Chanda Sanjay
Chief Development Officer
Chanda Sanjay has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 23, 2026.
On the most recent filing, Chanda Sanjay is listed as Chief Development Officer at AN2 Therapeutics, Inc. Inside the rolling window, Chanda Sanjay reported no open-market purchases and 2 open-market sales totaling $9K in ANTX. The largest disclosed transaction in the window is a sale of 5,956 ANTX shares on Jan 6, 2026, worth $6K.
Companies traded
Other insiders at ANTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$9K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Chanda Sanjay made?
Chanda Sanjay has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Chanda Sanjay trade?
Chanda Sanjay has filed SEC Form 4 disclosures for 1 company, including ANTX.
When was Chanda Sanjay's most recent SEC Form 4 filing?
Chanda Sanjay's most recent SEC Form 4 filing on Tracefour is dated Feb 23, 2026.
What is Chanda Sanjay's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Chanda Sanjay is listed as Chief Development Officer.
What is Chanda Sanjay's total buy and sell value in the current window?
Inside the rolling retention window, Chanda Sanjay bought $0 and sold $9K based on SEC Form 4 filings.
What was Chanda Sanjay's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 5,956 ANTX shares on 2026-01-06, worth $6K, per SEC Form 4 filings.